Form 4: Zimmer Biomet Director Boosts Phantom Stock Holdings

Zimmer Biomet Holdings, Inc. Director Louis Shapiro acquired 140.163 phantom stock units as part of a deferred compensation plan.

Summary

• Louis Shapiro, a Director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 140.163 phantom stock units.
• The acquisition occurred on September 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The phantom stock units convert to common stock on a 1-for-1 basis.
• Following this transaction, Shapiro beneficially owns 2,342.509 phantom stock units.
• The total includes 5.316 phantom stock units accrued on July 31, 2025, through a dividend reinvestment provision.
• The units will be settled in shares of company common stock within sixty days after Shapiro ceases service as a Director.

Sentiment

Score: 6

Explanation: The filing indicates a routine compensation event where a director increases their beneficial ownership through phantom stock units. This is generally neutral to slightly positive as it aligns director interests with shareholders, but it is not a direct open market purchase.

Positives

• Increased beneficial ownership by a director, aligning their interests with shareholders.
• The transaction is part of a structured deferred compensation plan, indicating a routine compensation event.

Negatives

• No direct negatives identified in this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The phantom stock units are scheduled to be settled in shares of Zimmer Biomet Holdings, Inc. common stock within sixty days after Louis Shapiro ceases his service as a Director.

Industry Context

This filing represents a routine insider transaction related to director compensation within the medical technology industry. Such transactions are common for publicly traded companies as part of their executive and director remuneration structures, aiming to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The use of phantom stock units as part of a deferred compensation plan for non-employee directors is a standard practice across various industries, including medical technology.
• Companies like Stryker Corporation (SYK) and Medtronic plc (MDT) also utilize similar equity-based compensation structures to incentivize directors and retain talent, aligning their financial interests with company performance and shareholder returns.
• The 1-for-1 conversion ratio and settlement upon cessation of service are typical terms for such arrangements.

Related Party Transactions

• Acquisition of phantom stock units by Director Louis Shapiro under the company's Deferred Compensation Plan for Non-Employee Directors.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through equity-based compensation.
• Employees: No direct impact on general employees mentioned.
• Management: No direct impact on management beyond the reporting director.

Next Steps

• Settlement of phantom stock units into common stock within sixty days after Louis Shapiro's cessation of service as a Director.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it shows continued alignment of director interests with the company, it does not present new information that would fundamentally alter the investment thesis for Zimmer Biomet Holdings, Inc. It is a standard compensation event and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Zimmer Biomet, ZBH, Louis Shapiro, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Deferred Compensation Plan, Equity Holdings